GSK secures China NMPA approval for Nucala in eosinophilic COPD, targeting hospitalisation risk
GSK PLC (LSE/NYSE: GSK) has received regulatory approval from the National Medical Products Administration of China for Nucala (mepolizumab) as an add-on maintenance therapy for adults with eosinophilic chronic obstructive pulmonary disease (COPD) inadequately controlled on inhaled triple therapy. The greenlight marks a strategic respiratory expansion for GSK in the world’s largest COPD market and […]